Going into tomorrow's earnings report from Sarepta Therapeutics, the Street is expecting a significant increase to FY17 guidance, which may not materialize, Janney Capital analyst Debjit Chattopadhyay tells investors in a pre-earnings research note. The FY17 consensus estimate for Exondys51 sales is $96M versus management's guidance of $80M-plus, the analyst points out. Chattopadhyay believes Sarepta shares could be pressured if guidance is not materially higher than the consensus since the stock is up $7 since April 11. The analyst continues to like Sarepta's intermediate to long-term outlook and recommends buying the shares on any meaningful pullbacks. Chattopadhyay has a Buy rating on the shares with a $65 fair value estimate. Sarepta in morning trading is down 58c to $35.23.